The Specialty Pharmacy Review Board™ — Assessing the Evolving Value of Rheumatoid Arthritis Therapies

• Release Date: July 17, 2017
• Expiration Date: January 31, 2019
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

REVIEW BOARD FACULTY

Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography Steven G. Avey, MS, RPh, FAMCP Vice President, Specialty Pharmacy Programs MedImpact Healthcare Systems, Inc. Click here for biography Robin Dore, MD Clinical Professor of Medicine David Geffen School of Medicine UCLA Click here for biography Fadia Tohme-Shaya, PhD, MPH Professor and Vice Chair for Academic Affairs University of Maryland School of Pharmacy Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with rheumatoid arthritis including: physicians, pharmacists, and nurses

STATEMENT OF NEED/PROGRAM OVERVIEW

There is no cure for rheumatoid arthritis (RA), but new effective drugs are increasingly available to treat the disease and prevent deformed joints. Currently, the RA therapeutic pipeline is robust and includes agents that utilize novel mechanisms of action (MOAs) and various administration strategies (eg, oral, subcutaneous injection).

The educational format of The Specialty Pharmacy Review Board™ will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Assess decision support tools to enhance medical and pharmacy benefit design decision-making for patients with RA
• Interpret results of decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA
• Employ specialty pharmacy and disease management services that can improve the quality of care for patients with RA
• Provide accurate and appropriate counsel as part of the managed care treatment team

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-17-098-H01-P.

Type of Activity: Knowledge

Nursing Continuing Education

Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. MER is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
This CE activity provides 1.0 contact hours of continuing nursing education.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Inc., Impact Education, LLC, and/or Lilly USA, LLC. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Inc., Impact Education, LLC, and/or Lilly USA, LLC. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CPE credit for this activity. During the period July 17, 2017 through January 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.